Xarelto Lawsuit News: New Study Says Treatment Strategies For Venous Thromboembolisms Have Bleeding Risks Reports Wright & Schulte LLC

Share Article

As Xarelto Bleeding Lawsuits Continue To Be Filed, New Study Shows Bleeding Events Could Still Occur In Patients Taking Anticoagulant Medications

Xarelto Bleeding Lawsuit

New Study Says Treatment Strategies For Venous Thromboembolisms Have Bleeding Risks

If you believe you have suffered internal bleeding due to Xarelto contact the attorneys at Wright & Schulte LLC For a Free legal consult buy calling 1-800-399-0795 or visit www.yourlegalhelp.com or call

Wright & Schulte LLC reports a recently released study found that most treatment options for blood clots in veins (venous thromboembolisms) are equally safe and effective yet major bleeding occurred in patients using the anticoagulants including Xarelto. The research, published in the September 17, 2014 issue of the Journal of the American Medical Association, examined eight different anticoagulant drugs, including unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH), combined with vitamin K antagonists, which are also anticoagulants. Researchers from the University of Ottawa, Ontario, Canada, also included 45 randomized trials, which had a total number of 44,989 patients in their analyses. The study found nearly half of a percentage (0.49 percent) of patients had a major bleeding event during three months of treatment with Xarelto (rivaroxaban), and 0.29 percent had a major bleeding episode with Eliquis. The study's authors concluded that, except for the UFH-vitamin K antagonist combination, all other treatment strategies had bleeding risks similar to the LMWH-vitamin K antagonist combination. As studies continue on the effectiveness of anticoagulants such as Xarelto, court records indicate that Xarelto lawsuits allege that major bleeding events are side-effects of taking the Xarelto blood thinner and there is no antidote to reverse the uncontrolled bleeding, one of which was filed the U.S. District Court, Eastern District of New York (Case No. 1:14-cv-04841-FB-VMS)
[media.jamanetwork.com/news-item/study-compares-effectiveness-of-treatments-for-blood-clots/, September 16, 2014.]

The attorneys at Wright & Schulte continue to investigate claims of uncontrolled bleeding due to Xarelto and offer free legal claims to men and women who believe they have experienced bleeding side-effects from Xarelto and other anticoagulant drugs by calling 1-800-399-0795 or by visiting http://www.yourlegalhelp.com for information on this and other medication news.

Xarelto is a new-generation oral blood thinner first approved by the U.S. Food & Drug Administration (FDA) in July 2011 to reduce deep vein thrombosis and pulmonary embolism in patients who had knee or hip replacement surgery. In November 2011, FDA expanded approval for Xarelto to treat deep being thrombosis. In November 2012, Xarelto was approved to treat and prevent recurrence of deep vein thrombosis and pulmonary embolism and to reduce the risk of the conditions recurring following initial treatment. Unlike warfarin (Coumadin, Jantoven), a blood thinner approved by the FDA in 1954, Xarelto does not have a specific reversal agent should significant bleeding occur. Vitamin K is used as the antidote for patients taking warfarin.
[fda.gov/newsevents/newsroom/pressannouncements/ucm326654.htm, November 2, 2012]
[fda.gov/Drugs/NewsEvents/ucm405148.htm, July 17, 2014]

Court documents indicate that Xarelto lawsuits are being filed in courts throughout the United States, including a wrongful death lawsuit filed on August 14, 2014, in the U.S. District Court, Eastern District of New York on behalf of a 92-year-old Tennessee man. (Case No. 1:14-cv-04841-FB-VMS) According to the Xarelto complaint, the Tennessee man first began using the blood thinner medication from May 2013 and continued to use until August 2013. The Xarelto lawsuit alleges that due to using Xarelto, the man suffered life-threatening bleeding on August 25, 2013, and sustained severe and permanent personal injuries, pain, suffering and emotional distress. The man died on December 6, 2013. The Xarelto complaint purports that defendants Jannssen Pharmaceuticals and Bayer failed to warn emergency room doctors and other medical professionals as well as disclose to patients that there is no effective agent to reverse the anticoagulation effects of Xarelto, and therefore there is no effective means to treat and stabilize patients who experience uncontrolled bleeding while taking Xarelto.

About Wright & Schulte LLC
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free low testosterone lawsuit case evaluations are available through yourlegalhelp.com or by calling 1-800-399-0795.

Contact:
Wright & Schulte LLC
812 East National Road
Vandalia, Ohio 45377
1-800-399-0795
http://www.yourlegalhelp.com
Like us on Facebook
Follow us on Twitter
Join us on Google+

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Richard Schulte

Corey Artim
Follow us on
Visit website